BRIEF-Mabion Partner Oddifact Says FDA Consultations Allow MabionCD20 To Be Used As First-Line Therapy For ITP

Oct 20 (Reuters) – Mabion SA: * PARTNER ODDIFACT SAYS FDA CONSULTATIONS ALLOW MABIONCD20 TO BE USED AS FIRST-LINE THERAPY FOR ITP * CLINICAL TRIAL OBSERVATION PERIOD FOR MABIONCD20 CAN BE SHORTENED TO

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)